** Shares of Anavex Life Sciences AVXL.O fall 6% to $3.15

** The biotech firm says it has appointed Terrie Kellmeyer as interim chief executive after terminating the employment of long‑time CEO Christopher Missling, who has led it since 2013

** Kellmeyer, a former senior vice-president of clinical development at Anavex, takes over following Missling's departure on April 30

** Anavex says Missling was terminated for cause after a board review of conduct it believed was inconsistent with company policy and that he was also asked to resign as a director

** The company says it expects to delay filing its quarterly financial report and plans to provide more details on a future investor call

** Including sessions moves, stock down ~11% YTD